Skip to main content

Table 1 Demographic and clinical characteristics of the 38 leprosy patients according to aPL positivity or negativity on sera collected in 2010/2011

From: Epidemiological, clinical and immune factors that influence the persistence of antiphospholipid antibodies in leprosy

VariablesSerum aPL (2010/2011 collected sera)p
NegativePositiveTotal
n%n%N%
Gender0.670*
 Male583.3%2371.9%2873.7%
 Female116.7%928.1%1026.3%
 Age37.0 ± 18.248.1 ± 16.046.3 ± 16.60.075**
 Length of treatment81.2 ± 18.377.4 ± 36.580.0 ± 34.10.389**
Clinical presentations0.081*
 BT116.7%825.0%923.7%
 BB233.3%13.1%37.9%
 BV233.3%721.9%923.7%
 LL116.7%1650.0%1744.7%
Reactional episodes1*
 Present00.0%13.1%37.9%
 Absent6100.0%3196.9%3592.1%
Current reactional episodes1*
 Present116.7%39.4%410.5%
 Absent583.3%2990.6%3489.5%
Medication0.188*
 No583.3%1546.9%2052.6%
 Yes116.7%1753.1%1847.4%
Prednisone0.278*
 No00.0%423.5%422.2%
 Yes1100.0%1376.5%1477.8%
Thalidomide0.387*
 No00.0%635.3%633.3%
 Yes1100.0%1164.7%1266.7%
  1. * Chi-square test ** Mann-Whitney Test